BioAtla BCAB
OTC BCAB
$1.50 -0.10 (-6.25%)
At close: Sep 29, 2026 · 4:00 PM EDT

BioAtla (BCAB) EBITDA Margin (2020 - 2026)

Updated

BioAtla (BCAB) recorded EBITDA Margin of 3.49% in Q2 2026.

Analysis

BioAtla (BCAB) EBITDA Margin (2020 - 2026) Analysis & Trends

On a TTM basis, BioAtla's EBITDA Margin came in at -375.65% as of Jun 30, 2026, up 197.27 percentage points year-over-year; for FY2025, it was -2946.60%, down 2282.80 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of +3834.52 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -663.80% in FY2024 and -38044.00% in FY2021 (-31262.88 pp).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 35.95%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 49.01%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 6.02%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 33.11%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 39.10%
10 BioAtla 2.49 Mn 2.49 Mn - 3.49%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.49%
Dec 31, 2025 -461.80%
Sep 30, 2024 -100.38%
Jun 30, 2021 -12,053.20%
Sep 30, 2020 -5,153.33%
Jun 30, 2020 -2,265.79%
Mar 31, 2020 -1,003.37%
API Access

BioAtla EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=BCAB&period=max&api_key=YOUR_API_KEY